S&P 500   3,332.50 (+1.88%)
DOW   26,819.59 (+1.13%)
QQQ   278.15 (+2.40%)
AAPL   115.84 (+4.17%)
MSFT   206.48 (+1.87%)
FB   282.24 (+5.44%)
GOOGL   1,583.08 (+4.78%)
AMZN   3,238.61 (+2.40%)
TSLA   412.17 (+1.51%)
NVDA   525.25 (+3.99%)
BABA   314.76 (+2.21%)
CGC   18.69 (+1.91%)
GE   7.38 (-0.54%)
MU   50.63 (+1.26%)
AMD   78.72 (+3.04%)
T   26.90 (+1.51%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.69 (-0.05%)
NFLX   484.22 (-0.42%)
NIO   31.63 (+14.98%)
BA   148.39 (+0.17%)
DIS   121.27 (+2.36%)
S&P 500   3,332.50 (+1.88%)
DOW   26,819.59 (+1.13%)
QQQ   278.15 (+2.40%)
AAPL   115.84 (+4.17%)
MSFT   206.48 (+1.87%)
FB   282.24 (+5.44%)
GOOGL   1,583.08 (+4.78%)
AMZN   3,238.61 (+2.40%)
TSLA   412.17 (+1.51%)
NVDA   525.25 (+3.99%)
BABA   314.76 (+2.21%)
CGC   18.69 (+1.91%)
GE   7.38 (-0.54%)
MU   50.63 (+1.26%)
AMD   78.72 (+3.04%)
T   26.90 (+1.51%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.69 (-0.05%)
NFLX   484.22 (-0.42%)
NIO   31.63 (+14.98%)
BA   148.39 (+0.17%)
DIS   121.27 (+2.36%)
S&P 500   3,332.50 (+1.88%)
DOW   26,819.59 (+1.13%)
QQQ   278.15 (+2.40%)
AAPL   115.84 (+4.17%)
MSFT   206.48 (+1.87%)
FB   282.24 (+5.44%)
GOOGL   1,583.08 (+4.78%)
AMZN   3,238.61 (+2.40%)
TSLA   412.17 (+1.51%)
NVDA   525.25 (+3.99%)
BABA   314.76 (+2.21%)
CGC   18.69 (+1.91%)
GE   7.38 (-0.54%)
MU   50.63 (+1.26%)
AMD   78.72 (+3.04%)
T   26.90 (+1.51%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.69 (-0.05%)
NFLX   484.22 (-0.42%)
NIO   31.63 (+14.98%)
BA   148.39 (+0.17%)
DIS   121.27 (+2.36%)
S&P 500   3,332.50 (+1.88%)
DOW   26,819.59 (+1.13%)
QQQ   278.15 (+2.40%)
AAPL   115.84 (+4.17%)
MSFT   206.48 (+1.87%)
FB   282.24 (+5.44%)
GOOGL   1,583.08 (+4.78%)
AMZN   3,238.61 (+2.40%)
TSLA   412.17 (+1.51%)
NVDA   525.25 (+3.99%)
BABA   314.76 (+2.21%)
CGC   18.69 (+1.91%)
GE   7.38 (-0.54%)
MU   50.63 (+1.26%)
AMD   78.72 (+3.04%)
T   26.90 (+1.51%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.69 (-0.05%)
NFLX   484.22 (-0.42%)
NIO   31.63 (+14.98%)
BA   148.39 (+0.17%)
DIS   121.27 (+2.36%)
Log in
NASDAQ:REPH

Recro Pharma Stock Forecast, Price & News

$1.67
-0.09 (-5.11 %)
(As of 10/29/2020 02:28 PM ET)
Add
Compare
Today's Range
$1.65
Now: $1.67
$1.73
50-Day Range
$1.85
MA: $2.15
$2.48
52-Week Range
$1.76
Now: $1.67
$19.21
Volume4,682 shs
Average Volume413,401 shs
Market Capitalization$39.48 million
P/E Ratio8.35
Dividend YieldN/A
Beta0.61
Recro Pharma, Inc. a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Read More
Recro Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470
Employees213

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$99.22 million
Cash Flow$0.45 per share
Book Value($0.30) per share

Profitability

Net Income$-18,630,000.00

Miscellaneous

Market Cap$39.48 million
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$1.67
-0.09 (-5.11 %)
(As of 10/29/2020 02:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

How has Recro Pharma's stock been impacted by Coronavirus (COVID-19)?

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REPH shares have decreased by 82.0% and is now trading at $1.65.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Recro Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Recro Pharma
.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Recro Pharma
.

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) issued its earnings results on Monday, August, 10th. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.09. The specialty pharmaceutical company earned $15.52 million during the quarter, compared to the consensus estimate of $19 million.
View Recro Pharma's earnings history
.

What price target have analysts set for REPH?

2 analysts have issued 12-month target prices for Recro Pharma's stock. Their forecasts range from $12.00 to $18.00. On average, they anticipate Recro Pharma's stock price to reach $15.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price.
View analysts' price targets for Recro Pharma
.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 651,600 shares, an increase of 13.3% from the September 30th total of 574,900 shares. Based on an average daily trading volume, of 314,200 shares, the short-interest ratio is currently 2.1 days. Currently, 3.3% of the shares of the stock are sold short.
View Recro Pharma's Short Interest
.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the following people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 68, Pay $952.25k)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 43, Pay $572.13k)
  • Mr. Randall J. Mack, Sr. VP of Devel. (Age 55)
  • Mr. Marshall Rizzo M.B.A., Exec. VP & GM of Contract Manufacturing Facility
  • Dr. Stewart McCallum, Chief Medical Officer (Age 54)

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (2.76%) and Wedbush Securities Inc. (0.20%). Company insiders that own Recro Pharma stock include Arnaud Ajdler and Geraldine Henwood.
View institutional ownership trends for Recro Pharma
.

Which major investors are buying Recro Pharma stock?

REPH stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Wedbush Securities Inc..
View insider buying and selling activity for Recro Pharma
.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $1.65.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $39.01 million and generates $99.22 million in revenue each year. The specialty pharmaceutical company earns $-18,630,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Recro Pharma employs 213 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is www.recropharma.com.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.